Business

VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS AND COMMITTEE APPOINTMENTS

VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS AND COMMITTEE APPOINTMENTS.

articleValeo Pharma Inc.April 28, 20233/company/valeo-pharma-inc/news/valeo-pharma-announces-results-of-annual-meeting-of-shareholders-and-committee-appointments
VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS AND COMMITTEE APPOINTMENTS

About this update from Valeo Pharma Inc.

[{"type":"text","content":"\n\n\n\nVALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS AND COMMITTEE APPOINTMENTS\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen3{\nPADDING-RIGHT:0.17em; PADDING-LEFT:0.17em; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: LEFT; BORDER-TOP:black 1pt; BORDER-RIGHT:black 1pt; BORDER-BOTTOM:black 1pt; BORDER-LEFT:black 1pt\n}\n.prngen5{\nPADDING-RIGHT:0.17em; PADDING-LEFT:0.17em; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; BORDER-TOP:black 1pt; BORDER-RIGHT:black 1pt; BORDER-BOTTOM:black 1pt; BORDER-LEFT:black 1pt\n}\n.prngen4{\nPADDING-RIGHT:0.17em; PADDING-LEFT:0.17em; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; BORDER-TOP:black 1pt; BORDER-RIGHT:black 1pt; BORDER-BOTTOM:black 1pt; BORDER-LEFT:black 1pt\n}\n.prngen2{\nPADDING-RIGHT:0.17em; PADDING-LEFT:0.17em; VERTICAL-ALIGN: BOTTOM; BORDER-TOP:black 1pt; BORDER-RIGHT:black 1pt; BORDER-BOTTOM:black 1pt; BORDER-LEFT:black 1pt\n}\n.prnml4{\nMARGIN-TOP:0em; MARGIN-RIGHT:0em; MARGIN-BOTTOM:0em; MARGIN-LEFT:0.33em !IMPORTANT\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n\n\n\n\n\n\nVALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS AND COMMITTEE APPOINTMENTS\nCanada NewsWire\nMONTREAL, April 28, 2023\n\n\n\nMONTREAL, April 28, 2023 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE:VP2) (\"Valeo\" or the \"Company\"), a Canadian pharmaceutical company, today announced the results of the proposals submitted to shareholders at its annual meeting of shareholders held on April 27, 2023 (the \"Meeting\").\n\n \n \n \n \n \n \n\n \nElection of Directors\nThe results of the vote for those elected as directors are as follows:\nNominees\nVotes For\nVotes Against\nNumber of Shares\n%\nNumber of Shares\n%\nSteve Saviuk\n30,736,915\n97.28\n859,400\n2.72\nRichard MacKay\n30,737,015\n97.28\n859,300\n2.72\nMarc Léger\n30,737,015\n97.28\n859,300\n2.72\nMaureen Brennan\n31,423,715\n99.45\n172,600\n0.55\nMichel Trudeau\n31,417,005\n99.43\n179,310\n0.57\nStuart W. Fowler\n31,448,115\n99.53\n148,200\n0.47\nApppointment of the auditor\nThe results of the vote for the appointment of PricewaterhouseCoopers LLP as the au...

More updates from Valeo Pharma Inc.